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terms, certain lines of development were
undertaken: (1) Development of an electro-
phoresis apparatus which was stable and easy
to operate; (2) to increase the percentage
slowing of the macrophages so that recog-
nition of such cells would be prone to less
error; (3) characterization of the component
produced and released by the sensitized
lymphocytes-the macrophage slowing factor
MSF; (4) evaluation of the test in non-
malignant disease situations.
A new electrophoresis apparatus has been
designed and built. This apparatus has
formed the basis of many modifications and
is now in the process of evaluation with
close-circuit television. The new apparatus
allows for a greater number of samples to be
measured, associated with minimum operator
fatigue.
The percentage slowing of macrophages,
and hence the percentage positivity obtained
in the MEM test, can be increased by in-
creasing the number of lymphocytes in the
test system and increasing the radiation dose
to the macrophages. Percentage macrophage
slowing can also be increased by adopting a
split incubation regimen viz. (1) Lymphocytes
and antigen 23°C 90 min-supernatant from
(1) to guinea-pig macrophages-37°C 90 min.
This modification has resulted in the per-
centage slowing from malignant conditions
being increased from the standard range
15-20% to 23-40% without any correspond-
ing effect on the " normals ". This MOD-
MEM test has now been adopted as standard.
Electron micrograph studies of lympho-
cyte cell surfaces and macrophage cell
surfaces have failed to reveal any visible
changes. Column chromatography (Sepha-
dex) has shown that the slowing factor may
be split into two active components of
differing molecular weight; one component of
M.W. 20,000 and another of M.W. 8000, the
latter being capable of producing more
macrophage slowing than the former. Slow-
ing factor is heat stable. Attempts to detect
slowing factor on S.D.S. polyacrylamide gel
electrophoresis were unsuccessful because of
concentration effects and lack of reproduci-
bility. Histone fractions F2A1 and F2A2
have been shown to have a sequence analogy
with the basic encephalogenilitic factor used
as the " antigen " in the MOD-MEM test.
These fractions can replace the EF as
antigen but concentrations have to be
carefully monitored as such histone prepara-
tions are nonspecific in causing macrophage
slowing.
The results of a small pilot study of the
operation of the MEM test in non-malignant
disease indicated that the specificity of the
test for cancer was notnecessarily maintained.
In general, specific inflammatory and meta-
bolic disease did not produce results within
the cancer range. Degenerative diseases
involving nerve tissue produced positive
results within the cancer range. Pregnanev
did not give positive results. Of 115 cases
studied, 13 gave positive results in the MOD-
MEM test, where sensitization could not be
attributed to a specific cause. This group
consisted of subjects suffering from chronic
bronchitis, rheumatic fever and duodenal
ulcers. Thesecases arebeingfollowed. One case
of adenocarcinoma and disseminated sclerosis
gave negative MOD-MEM results.
CLINICAL EXPERIENCE WITH THE
MAKARI TUMOUR SKIN TEST. D.E.H.
TEE. Department of Immunology, King's
College Hospital Medical School.
The double-blind evaluation ofthe Makari
intradermal test was started nearly 5 years
ago and is still continuing. The test is based
upon the measurement of the local erythe-
matous reactions of the skin to a series of
intradermal injections of cancer derived
antigens which have been pre-incubated with
the patient's serum. These antigens have
been prepared from human tumour material
by the application of major physical and
chemical degradative procedures. The
patients examined were those referred to
King's College Hospital, the majority ofwhom
had signs and symptoms which suggested the
presence of malignant disease.
Our previously published studies, the last
of which consisted of 584 patients, have
confirmed that positive intradermal tests are
seen in many, but not all, patients with
malignant tumours arising in different organs,
including those of the digestive, respiratory
and genito-urinary systems. In subjects with
carcinoma the response to the test was
related to the stage of the carcinomatous
process, the largest proportion of positive
tests occurring in patients with early disease.
An appreciable proportion of positive test
results were also observed in diseases asso-
ciated with inflammatory and reactive pro-
cesses. Thus, our published studies suggestedSYMPOSIUM 187
that, in practical terms, the test was not
suitable in its present form for routine
cancer screening. However, the relatively
high percentage of positive tests in early
cancer indicate the possible role ofmonitoring
the patients' response to treatment, in
detecting the recurrence of tumour at an
early stage and in differential diagnosis.
Further studies are currently in hand to
investigate the possible role of the Makari
intradermal test in the monitoring ofresponse
to treatment and in the early detection of
recurrent tumour. The preliminary results
of these studies indicate that the surgical
removal of a tumour may lead to the conver-
sion of the Makari skin test from positive to
negative and during the follow-up period a
negative test may convert to positive on the
appearance of local or distant recurrence of
the tumour. It is important to stress that
these data are of a preliminary nature and
that further experience is required with more
cases and a considerably longer period of
follow-up. Nevertheless, the present data
strongly support the need for further studies
in relation to the monitoring oftreatment and
the detection of recurrent tumour.
THE VALUE OF HORMONE MEAS-
UREMENTS IN TUMOUR MANAGE-
MENT. K. D. BAGSHAWE. Department of
Medical Oncology, Charing Cross Hospital,
London
The practice of measuring hormones and
other substances produced by tumours, or by
specific organs in response to tumours, is
becoming a major occupation in the cancer
field. One of the problems is to match the
resources available to the problems which can
be defined and the distinction between
research and clinical routine operation re-
quires constant assessment. The range of
possible measurements is already very wide
and the number of patients to whom tests
are applicable is already large even though
most of the measurements do not yet relate
to the commonest malignancies.
The measurement of tumour products as
diagnostic aids is well established as a means
ofdistinguishing between neoplastic and non-
neoplastic causes for certain rare but " in-
teresting" syndromes. But some important
applications are slow to reach clinical prac-
tice, possibly because the conditions them-
selves are not regarded as "interesting" to
physicians.
Measurements may be applied to prob-
lems oftumour localization. Selective venous
sampling probably has a limited area of
application but it has a requirement for
precision in measurements which is not
readily sustained on a routine basis. Locali-
zation of tumours within the CNS can take
advantage of the blood-brain barrier and
although such methods have been available
for gonadotrophin producing tumours for the
past decade, their use has not been widespread
even though they are of substantial practical
value.
Screening operations based on tumour
products are valid for only a limited range of
tumours at the present time. Again, the
interval between developing a technology
appropriate to such a problem and putting it
into clinical operation may be very long. In
the case of uncommon tumours, screening
programmes are practicable only if carried
out on a regional or national basis.
The concept of monitoring the clinical
course of tumours with serial measurements
has been established for a limited range of
tumours and it is clear that it may sometimes
be necessary to follow more than a single
indicator substance. Different indicator
substances may provide different forms of
information and the form of information
provided by a given indicator substance may
be different for different tumours.
Nevertheless, some propositions currently
discussed in this field should perhaps be
examined critically. Do we really mean
" predictive " tests? Also, where we are
threatened by complexity we should perhaps
seek to avoid it at the outset and extract a
maximum of information from the simplest
measurements. " Multiparametric Analysis "
is not an end in itself and may be a passing
reflection of present inadequacies.
HORMONES AND THE PROSTATE.
K. GRIFFITHS. Tenovus Institute for Cancer
Research, Welsh National School ofMedicine,
Cardiff.
Regression of prostatic carcinoma in a
large proportion of patients treated by anti-
androgen therapy, either castration or oestro-
gen administration, clearly indicates the